Charles Schwab Investment Management Inc. Purchases 768 Shares of argenx SE (NASDAQ:ARGX)

Charles Schwab Investment Management Inc. raised its position in argenx SE (NASDAQ:ARGX) by 28.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,459 shares of the company’s stock after acquiring an additional 768 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in argenx were worth $1,875,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Blue Trust Inc. lifted its stake in argenx by 620.0% in the 2nd quarter. Blue Trust Inc. now owns 72 shares of the company’s stock valued at $28,000 after purchasing an additional 62 shares during the last quarter. Point72 Hong Kong Ltd acquired a new stake in shares of argenx in the second quarter valued at approximately $76,000. Cromwell Holdings LLC boosted its stake in shares of argenx by 73.3% during the 3rd quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock worth $85,000 after acquiring an additional 66 shares during the period. GAMMA Investing LLC increased its holdings in shares of argenx by 47.5% during the 3rd quarter. GAMMA Investing LLC now owns 174 shares of the company’s stock worth $94,000 after acquiring an additional 56 shares during the last quarter. Finally, Raymond James Trust N.A. bought a new stake in argenx in the 2nd quarter valued at $201,000. Institutional investors own 60.32% of the company’s stock.

argenx Stock Up 4.2 %

Shares of argenx stock opened at $632.64 on Tuesday. argenx SE has a 12-month low of $327.73 and a 12-month high of $643.63. The company has a market capitalization of $38.19 billion, a price-to-earnings ratio of -718.91 and a beta of 0.59. The firm’s 50-day moving average price is $583.23 and its two-hundred day moving average price is $517.38.

argenx (NASDAQ:ARGX) last issued its quarterly earnings results on Thursday, October 31st. The company reported $1.39 earnings per share for the quarter, topping analysts’ consensus estimates of $0.10 by $1.29. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The company had revenue of $588.88 million during the quarter, compared to the consensus estimate of $543.29 million. During the same quarter in the prior year, the firm posted ($1.25) EPS. On average, sell-side analysts expect that argenx SE will post 2.2 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Scotiabank raised shares of argenx from a “sector perform” rating to a “sector outperform” rating and lifted their price objective for the stock from $439.00 to $715.00 in a research report on Tuesday, November 5th. Wedbush reiterated an “outperform” rating and issued a $655.00 price target on shares of argenx in a research note on Tuesday, December 3rd. Oppenheimer reissued an “outperform” rating and issued a $675.00 price target (up from $646.00) on shares of argenx in a report on Thursday, November 21st. HC Wainwright restated a “buy” rating and set a $617.00 price objective on shares of argenx in a report on Wednesday, November 20th. Finally, Baird R W downgraded argenx from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 1st. Three investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $635.11.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.